Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy.
Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million.
The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results…
Zymeworks must be spending a fortune on pens as it inks yet another deal, this time with Johnson & Johnson’s biotech unit.
The heavily pretreated bladder cancer data suggest the cocktail can hold its own against a combination of rival drugs from Incyte and Merck.
Roivant’s Vivek Ramaswamy didn't sugarcoat its Alzheimer’s flop but said his company won't back away from the field.
The trials linked the drug to improvements on a depression scale, teeing Sage up to file for approval next year and sending its stock up 44%.
Just weeks after a phase 3 setback caused it to slash staff and R&D programs, Otonomy has bounced back with a positive late-stage trial.
AstraZeneca and Amgen’s tezepelumab missed the primary endpoint in a phase 2a atopic dermatitis trial, raising doubts about its prospects.
Former Roche and Calico vet Hal Barron has become the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley.
Kerrisdale Capital Management, known for its activist short positions, has given Prothena the unwanted title of the “next big biotech blowup.”